NEW YORK (GenomeWeb News) – Gentronix today said that it will provide GlaxoSmithKline with its genotoxicity detection assay, GreenScreen HC, for use in the drug firm's safety evaluation studies.

According to Manchester, UK-based Gentronix, GreenScreen HC is the first human cell-based assay technology that combines high sensitivity for detecting genotoxic chemicals with high specificity for reducing false positive results. The assay uses green fluorescent protein to detect GADD-45a up regulation, which is a key indicator of DNA damage, said Gentronix.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.